Antimalarial Activities of New Guanidylimidazole and Guanidylimidazoline Derivatives

详细信息    查看全文

• 作者：Liang Zhang ; Ramadas Sathunuru ; Diana Caridha ; Brandon Pybus ; Michael T. O鈥橬eil ; Michael P. Kozar ; Ai J. Lin
• 刊名：Journal of Medicinal Chemistry
• 出版年：2011
• 出版时间：October 13, 2011
• 年：2011
• 卷：54
• 期：19
• 页码：6634-6646
• 全文大小：1099K
• 年卷期：v.54,no.19(October 13, 2011)
• ISSN：1520-4804

文摘

A series of new guanidylimidazole derivatives was prepared and evaluated in mice and Rhesus monkeys infected with malarial sporozoites. The majority of the new compounds showed poor metabolic stability and weak in vitro activities in three clones of Plasmodium falciparum. Compounds 8a, 8h, 9a, 16a, and 16e cured the mice infected with sporozoites of P. berghei at 160 and 320 mg/kg/day 脳 3 po. Compounds 8a showed better causal prophylactic activity than primaquine, tafenoquine, and Malarone in the Rhesus test. In the radical curative test, 8a cured one monkey and delayed relapse of another for 74 days at 30 mg/kg/day 脳 7 by im. By oral dosing, 8a delayed relapse 81 days for one and 32 days for other vs 11鈥?2 days for control monkeys treated with 10 mg/kg of chloroquine by po alone. Compound 8h, which showed superior activity to 8a in mouse test, delayed the relapse of treated monkeys for 21鈥?6 days at 30 mg/kg/day 脳 7 by oral.